Associate Director, Development Business Operations with over 15 years of experience in drafting, reviewing, and negotiating contractual and legal documents within the CRO/Pharmaceutical/Clinical Site environment, for both CROs and for sponsors. I am highly competent and knowledgeable at managing internal and external budgets, including site budgets, cash flow analysis, and revenue recognition through developing a range of cash positive payment schedules. My knowledge in proposal, contract, and budget development has been invaluable in the critical assessment of the multiple aspects of vendor proposals and contracts and in the selection of US and Ex-US vendors including in the evaluation of bid defences.
My experience in tracking and analysing internal and external metrics have helped ensure contractual timelines are met and critical study related milestones are achieved. My proven leadership qualities comprise global line management and project management which are evident through development, advancement and implementation of global contracting processes, template management, and document review processes designed to create efficiencies and ensure client and sponsor satisfaction.
My clinical research experience is supported through my degree in pharmacology which provides essential theoretical knowledge in a number of scientific research fields actively involved in clinical research trials.
A dynamic business leader with over 20 years of commercial experience at both biopharma and vendor companies. Strong scientific background with pharma/biotech clinical development and CRO/CDMO full-service phase I-IV sales experience and a deep understanding of drug development. Prolific networker with global contacts and a track record of negotiating and closing deals.
Bhakti Patel is a strategic clinical operations leader specializing in ophthalmology, medical devices, and drug/device combination trials. As Senior Director of Project Delivery within the Ophthalmology business unit, Bhakti leads global clinical delivery efforts with a focus on cross-functional collaboration, regulatory compliance, and operational efficiency.
With nearly two decades of experience across CRO, pharma, and site networks, she brings deep expertise in clinical trial management across all phases, including vendor oversight, risk mitigation, audit readiness, and data-driven process improvement. Her leadership has supported successful trials in a broad range of therapeutic areas, with particular depth in ophthalmology indications such as geographic atrophy, glaucoma, diabetic macular edema (DME), and gene therapy.
Prior to joining TFS, Bhakti held senior leadership roles at Velocity Clinical Research, Glaukos Corporation, and ORA, where she implemented scalable systems, enhanced site performance, and led inspection readiness across global studies. She is also known for building and mentoring high-performing teams that consistently deliver on time and with quality.
Bhakti holds a bachelor’s degree in Microbiology, Immunology, and Biochemistry and is a certified Lead Auditor. She is deeply committed to patient-centered research, continuous improvement, and empowering teams to drive lasting impact.
Ms. Claire Chin is a strategic leader at the intersection of life sciences investment and AI with over 15 years of cross-sector expertise spanning clinical medicine, strategic consulting, venture capital, and artificial intelligence. As Chief Industrial Advisor and Chief Strategy Officer at INTELLIGEN AI, she spearheads biomedical LLM ecosystem development. Holding an MBA from Kellogg School of Management and a clinical medicine dual degree from Shanghai Jiao Tong University, she uniquely bridges deep healthcare and business domains. As former Managing Director at Alibaba Health, head of investment in biopharma, her track record includes leading a $70M+ life science portfolio and securing Asia’s largest AI drug licensing deal ($1.3B per asset). She now pioneers collaborative AI innovation across 30+ institutions to transform drug discovery and precision medicine.
秦祯女士是生命科技投资与人工智能交叉领域的战略领袖，拥有逾15年横跨临床医疗、战略咨询、风险投资及AI产业的跨领域经验。现任INTELLIGEN AI首席产业顾问兼首席战略官，主导生物大语言模型生态建设。她拥有西北大学凯洛格商学院MBA及上海交通大学临床医学本硕学位，兼具顶尖医疗专业与商业战略双重背景。曾任阿里健康董事总经理兼创新药投资负责人，主导了超7000万美元的投资，并推动被投企业达成亚洲最大AI药物授权交易（单项目13亿美元）。目前致力于构建30余家机构的AI协同创新网络，加速药物研发与精准医疗突破。
Mr. Chester Xiao is the Director of Life Sciences for IDA Ireland in China. IDA Ireland is the investment promotion agency of the Irish Government. Over the past 50 years, IDA Ireland has successfully established Ireland as one of the world’s leading investment destinations and transformed Ireland into a ‘knowledge economy’. Now IDA Ireland supports more than 1,800 client companies and operates internationally from its base in Ireland.
肖嘉先生目前担任爱尔兰投资发展局（IDA）的中国区生命科学行业总监。爱尔兰投资发展局是爱尔兰政府的投资促进机构。在过去的五十年里爱尔兰投资发展局成功将爱尔兰打造为全球领先的投资目的地之一，成功实现爱尔兰向“知识经济”的转型。爱尔兰投资发展局支持1800多家客户企业，以爱尔兰为基地开展面向国际市场的业务。
Shelly graduated from Shenyang University of Chemical Technology with a major in Polymer Chemistry. She has over 15 years of experiences in commercial and clinical supply chain management in multinational pharmaceutical companies (MNCs) including Covance, Sanofi and Amgen, during which she supported the establishment of Asia-Pacific R&D centers, as well as multiple projects involving the launch, import and localization switching of products in China. At the meanwhile, she has also participated in the supply for Phase I-III clinical trials in China, the United States and the Asia-Pacific region in therapeutic areas such as oncology, metabolism and autoimmune diseases.
Shelly joined Eli Lilly China in 2023 and currently serves as the Head of Clinical and QC Supply Chain. She continues to promote China’s synchronous R&D strategy, strengthen the connection between local and global supply processes, ensure the supply of registered drugs, build team capabilities, and actively participate in the construction of external ecosystems related to clinical supply.
Shelly毕业于沈阳化工大学高分子化学专业，拥有超过15年在跨国制药企业（MNC）从事商业及临床供应链管理的经验。曾任职于科文斯、赛诺菲和安进等跨国药企，期间支持亚太研发中心的建立以及多个产品的中国上市、进口与本地化转产项目，并参与肿瘤、代谢、自身免疫等治疗领域的中美及亚太区域I~III期临床试验供应。Shelly于2023年加入礼来中国，现任临床及QC供应链负责人，持续推动中国同步研发策略，强化本地与全球供应流程衔接、注册用药保障及团队能力建设，并积极参与临床供应相关的外部生态系统建设。
Over 22 years of multinational corporation (MNC) experience in full lifecycle product development, real-world evidence, new product launch, pharmacovigilance, and GxP QMS compliance & auditing across oncology and specialty therapeutic areas.
Prior to DCTA and Trial Data, held positions at Roche China Medical Affairs and Eli Lilly Global R&D.
Master of Medicine in Hematology from Shanghai Jiao Tong University School of Medicine; practiced hematology at Hôtel-Dieu Hospital in Paris, France and Ruijin Hospital in Shanghai, China.
拥有超过22年跨国企业工作经验，负责全生命周期产品研发以及真实世界证据、新产品上市、药物安全警戒以及GxP质量管理体系合规与审计等多个方面，涉及多个肿瘤和特药治疗领域。
加入创达之前，先后在罗氏中国医学事务部、礼来全球研发担任多个职位。
毕业于上海交通大学医学院，获得血液学医学硕士学位，曾在法国巴黎Hotel Dieu Hospital和上海瑞金医院血液科就职参加临床工作。
Over 18 years of experience in clinical research and 9 years in digital CRO. Holds an MBA from The University of Hong Kong and is a pioneer in decentralized clinical trial (DCT) practices in China.
Previously worked at world-renowned companies such as Roche, PPD, and Chiltern, leading multiple large-scale regional studies as the China lead, managing projects across nearly 150 research sites.
Key Contributions: Co-author of *Real-World Research Guidelines 2018*; Co-author of Medical Code in the AI Era; Co-author of Blue Book on Remote & Intelligent Clinical Trials; Committee member of DIA (Drug Information Association), involved in oncology researcher training programs.
18余年临床研究领域经验，9余年医疗数字化创业经历。香港大学工商管理学硕士，DCT中国临床研究实践的先行者。
曾就职于罗氏、PPD、Chiltern等世界知名企业，参与多项大型regional study 任中国区负责人，负责近150家研究中心的项目管理工作。《真实世界研究指南2018 》执笔专家之一, 《AI时代医学密码》执笔专家之一，《远程智能临床试验蓝皮书》执笔专家之一，同时担任DIA组委会成员参与肿瘤研究者培训工作。
Dr. Li ZENG joined Jing Medicine as Chief Executive Officer in November 2021, bringing with him a wealth of R&D and business operation experience in the pharmaceutical industry with a career spanning over 18 years. He has held drug R&D, portfolio and project management positions of increasing responsibilities in multinational companies such as Novartis and Eli Lilly as well as in traditional local pharma and biotech firms such as Luoxin Pharmaceutical, 4B Technologies and Harbour Biomed.
Dr. Zeng received his bachelor’s degree in chemistry from Peking University and Ph.D. in Organic Chemistry from Stanford University. He conducted his postdoctoral research training in Chemical Biology at University of California, Berkeley.
曾雳博士于2021年11月加入和径医药担任首席执行官，拥有超过19年的新药研发和管理经验。曾博士先后在跨国药企诺华公司和礼来公司负责新药研发和项目管理，以及在罗欣药业、福贝生物和和铂医药等民营企业和生物技术公司负责战略规划和运营、新药产品线和项目管理。
曾博士分别在北京大学和斯坦福大学获得化学学士和有机化学博士学位，并在加州大学伯克利分校完成化学生物学的博士后训练。
